Transthera Sciences (Nanjing), Inc.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-04-15
- Employees
- 51
- Market Cap
- -
- Website
- http://www.transtherabio.com
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsCholangiocarcinoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Registration Number
- NCT06370013
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
- Conditions
- Cholangiocarcinoma Metastatic
- Interventions
- Drug: TT-00420 (tinengotinib)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06057571
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05948475
- Locations
- 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸The University of Kansas Cancer Center, Westwood, California, United States
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
- Conditions
- B-Cell Malignancies
- Interventions
- Drug: TT-01488 Tablets
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05683717
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: TT-00973-MS tablets treatment
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05673538
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
- Prev
- 1
- 2
- 3
- Next